NASDAQ: EDIT | Healthcare / Biotechnology / USA |
7.05 | -0.2800 | -3.82% | Vol 1.42M | 1Y Perf -43.40% |
Oct 4th, 2023 16:00 DELAYED |
BID | 6.97 | ASK | 7.36 | ||
Open | 7.32 | Previous Close | 7.33 | ||
Pre-Market | - | After-Market | 7.35 | ||
- - | 0.30 4.26% |
Target Price | 16.64 | Analyst Rating | Moderate Buy 2.18 | |
Potential % | 136.03 | Finscreener Ranking | ★★★+ 50.74 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★+ 49.94 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★ 50.80 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 9.11 | Earnings Rating | Strong Buy | |
Market Cap | 575.51M | Earnings Date | 1st Nov 2023 | |
Alpha | -0.01 | Standard Deviation | 0.26 | |
Beta | 1.79 |
Today's Price Range 6.997.32 | 52W Range 6.3314.23 | 5 Year PE Ratio Range -12.90-10.60 |
Summary:
Sell
Technical Indicators: | Neutral |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | 1.88% | ||
1 Month | -20.16% | ||
3 Months | -14.86% | ||
6 Months | 2.92% | ||
1 Year | -43.40% | ||
3 Years | -75.81% | ||
5 Years | -75.32% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -30.86 | |||
ROE last 12 Months | -44.12 | |||
ROA (5Y Avg) | -12.49 | |||
ROA last 12 Months | -35.33 | |||
ROC (5Y Avg) | -38.12 | |||
ROC last 12 Months | -39.15 | |||
Return on invested Capital Q | -12.48 | |||
Return on invested Capital Y | -7.25 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 75.20 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-3.10 | ||||
1.49 | ||||
42.90 | ||||
616.40 | ||||
-4.50 | ||||
-2.47 | ||||
1.49 | ||||
6.03 | ||||
220.55M | ||||
Forward PE | -2.91 | |||
PEG | -0.22 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
9.90 | ||||
10.10 | ||||
0.02 | ||||
0.05 | ||||
219.50 | ||||
Leverage Ratio | 1.20 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
-795.90 | ||||
-771.50 | ||||
-466.50 | ||||
-87.89 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
13.18M | ||||
0.19 | ||||
4.85 | ||||
34.13 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2023 | -0.76 | -0.56 | 26.32 |
Q01 2023 | -0.79 | -0.71 | 10.13 |
Q04 2022 | -0.84 | -0.88 | -4.76 |
Q03 2022 | -0.87 | -0.81 | 6.90 |
Q02 2022 | -0.84 | -0.78 | 7.14 |
Q01 2022 | -0.81 | -0.74 | 8.64 |
Q04 2021 | -0.78 | -0.61 | 21.79 |
Q03 2021 | -0.86 | -0.57 | 33.72 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
9/2023 QR | -0.64 | 14.67 | Positive |
12/2023 QR | -0.69 | 4.17 | Positive |
12/2023 FY | -2.55 | 15.56 | Positive |
12/2024 FY | -2.68 | 13.27 | Positive |
Next Report Date | 1st Nov 2023 |
Estimated EPS Next Report | -0.64 |
Estimates Count | 10 |
EPS Growth Next 5 Years % | 13.80 |
Volume Overview | |
---|---|
Volume | 1.42M |
Shares Outstanding | 81.63K |
Shares Float | 79.84M |
Trades Count | 14.69K |
Dollar Volume | 10.10M |
Avg. Volume | 1.94M |
Avg. Weekly Volume | 2.67M |
Avg. Monthly Volume | 1.70M |
Avg. Quarterly Volume | 1.44M |
Editas Medicine Inc. (NASDAQ: EDIT) stock closed at 7.05 per share at the end of the most recent trading day (a -3.82% change compared to the prior day closing price) with a volume of 1.42M shares and market capitalization of 575.51M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 235 people. Editas Medicine Inc. CEO is Cynthia Collins.
The one-year performance of Editas Medicine Inc. stock is -43.4%, while year-to-date (YTD) performance is -20.52%. EDIT stock has a five-year performance of -75.32%. Its 52-week range is between 6.33 and 14.23, which gives EDIT stock a 52-week price range ratio of 9.11%
Editas Medicine Inc. currently has a PE ratio of -3.10, a price-to-book (PB) ratio of 1.49, a price-to-sale (PS) ratio of 42.90, a price to cashflow ratio of 616.40, a PEG ratio of -0.22, a ROA of -35.33%, a ROC of -39.15% and a ROE of -44.12%. The company’s profit margin is -87.89%, its EBITDA margin is -771.50%, and its revenue ttm is $13.18 Million , which makes it $0.19 revenue per share.
Of the last four earnings reports from Editas Medicine Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.64 for the next earnings report. Editas Medicine Inc.’s next earnings report date is 01st Nov 2023.
The consensus rating of Wall Street analysts for Editas Medicine Inc. is Moderate Buy (2.18), with a target price of $16.64, which is +136.03% compared to the current price. The earnings rating for Editas Medicine Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Editas Medicine Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Editas Medicine Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 22.94, ATR14 : 0.48, CCI20 : -87.57, Chaikin Money Flow : -0.27, MACD : -0.41, Money Flow Index : 24.08, ROC : -12.63, RSI : 39.70, STOCH (14,3) : 28.37, STOCH RSI : 0.78, UO : 37.01, Williams %R : -71.63), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Editas Medicine Inc. in the last 12-months were: Bruce Eaton (Sold 4 536 shares of value $45 158 ), Eaton Bruce (Sold 4 765 shares of value $46 500 ), Mark S. Shearman (Sold 2 790 shares of value $26 966 ), Mei Baisong (Sold 4 317 shares of value $37 990 ), Michelle Robertson (Sold 6 416 shares of value $59 342 ), Robertson Michelle (Sold 7 172 shares of value $66 754 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Moderate Buy |
Editas Medicine Inc is a US-based genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company only operating segment being developing and commercializing genome editing technology.
CEO: Cynthia Collins
Telephone: +1 617 401-9000
Address: 11 Hurley Street, Cambridge 02141, MA, US
Number of employees: 235
Thu, 28 Sep 2023 20:46 GMT Editas Medicine upgraded to Buy from Hold at Stifel
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.